未登录

C

Cao, Ya

中南大学

H指数:0

被引数:11

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Circulating immune index predicting the prognosis of patients with hepatocellular carcinoma treated with lenvatinib and immunotherapy

FRONTIERS IN ONCOLOGY

IF3.3

2023-02-234

OAAI

Prognostic model for predicting outcome and guiding treatment decision for unresectable hepatocellular carcinoma treated with lenvatinib monotherapy or lenvatinib plus immunotherapy

FRONTIERS IN IMMUNOLOGY

IF5.9

2023-02-233

OAAI

Integration of Inflammation-Immune Factors to Build Prognostic Model Predictive of Prognosis and Minimal Residual Disease for Hepatocellular Carcinoma

整合炎症-免疫因子构建预测肝细胞癌预后及微小残留病的预后模型

FRONTIERS IN ONCOLOGY

IF3.3

2022-06-081

OAAI

Development of an Eight-gene Prognostic Model for Overall Survival Prediction in Patients with Hepatocellular Carcinoma

clinical and translational gastroenterology

IF4.2

2021-05-146

OAAI

Circulating Tumor Cells from Different Vascular Sites Exhibit Spatial Heterogeneity in Epithelial and Mesenchymal Composition and Distinct Clinical Significance in Hepatocellular Carcinoma

来自不同血管部位的循环肿瘤细胞在上皮和间质组成中表现出空间异质性，并在肝细胞癌中具有明显的临床意义

CLINICAL CANCER RESEARCH

IF10.2

2018-01-31127

OAAI

Overexpression of interleukin-35 associates with hepatocellular carcinoma aggressiveness and recurrence after curative resection

BRITISH JOURNAL OF CANCER

IF6.8

2016-03-2265

OAAI

(-)-Epigallocatechin-3-gallate inhibition of Epstein-Barr virus spontaneous lytic infection involves ERK1/2 and PI3-K/Akt signaling in EBV-positive cells

IF2.9

2012-11-2467

PREAI

The Tumor Suppressor UCHL1 Forms a Complex with p53/MDM2/ARF to Promote p53 Signaling and Is Frequently Silenced in Nasopharyngeal Carcinoma

CLINICAL CANCER RESEARCH

IF10.2

2010-05-31129

PREAI